Boehringer Ingelheim at AAPS 2026 PharmSci 360
Oct 25–28, 2026 New Orleans, LA ~4k attendees Website
Boehringer Ingelheim brings 10 presentations to AAPS 2026 PharmSci 360 in New Orleans. Its program centres on drug-drug interaction risk and immunogenicity testing, including anti-drug antibody assays for protein therapeutics. Its sessions also cover digital design of tablet formulations and long-acting drug delivery into the eye.
| Organization | AAPS 2026 PharmSci 360 Attendance |
|---|---|
Boehringer Ingelheim Ingelheim, Germany | |
Family-owned German pharmaceutical company with human and animal health medicines. | Poster Mon Oct 26 9:30am–10:30am ELISpot Assay to Detect Drug-Mediated Immunomodulation of Viral-Specific T Cell Responses Poster Mon Oct 26 12:30pm–1:30pm Addressing Challenges in Nonclinical ADA Assay Development for a Protein Therapeutic Poster Mon Oct 26 12:30pm–1:30pm Developing Validated DEM Modeling of a Twin-Screw Feeder for Enhanced Material Flow Analysis Talk Mon Oct 26 3:45pm–4:00pm Poster Tue Oct 27 9:30am–10:30am A Real-World Data (RWD)-Driven Approach to Characterize Concomitant Medication Use and Inform Drug-Drug Interaction Risk in Systemic Lupus Erythematosus Talk Tue Oct 27 1:30pm–2:30pm Poster Tue Oct 27 3:30pm–4:30pm Effects of Construct Design, Vendor Origin, and Conjugation Level on Bridging ECL ADA Assay Performance Poster Wed Oct 28 9:30am–10:30am Addressing Sensitivity Challenges of Modern Pharmacokinetic Immunocapture-LC/MS/MS Assays Through Extensive Capture Reagent and Surrogate Peptide Selection Talk Wed Oct 28 9:30am–10:00am |
Instantly find 20 buyers from Boehringer Ingelheim
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Association of Pharmaceutical Scientists (AAPS). Submit a correction